A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid

References

• Gertsner T, Bell N, Köning S. Oral valproic acid for epilepsy-long term experience in therapy and side effects. Expert Opin Pharmacother. 2008;9:285–92.
   PubMedGoogle Scholar
• Nalivaeva NN, Belyaev ND, Turner AJ. Sodium valproate: an old drug with new roles. Trends Pharmacol Sci. 2009;30:509–14.
   PubMedGoogle Scholar
• Chateviaux S, Morceau F, Dicato M, Diederich. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010; 2010:pii 479364.
   Google Scholar
• Donato MT, Martinez-Romero A, Jimenez N, Negro A, Herrera G, Castell JV, Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact. 2009;181:417–23.
   PubMed Web of Science ®Google Scholar
• Cotariu D, Zaldman JL. Valproic acid. Clin Chem. 1988;34:890–7.
   PubMed Web of Science ®Google Scholar
• Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, Valproate therapy and non-alcoholic liver disease. Ann Neurol. 2004;55:729–32.
   PubMed Web of Science ®Google Scholar
• Luef G, Rauchenzauner M, Waldmann M, Sturn W, Sandhofer A, Seppi K, Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009;86:42–7.
   PubMed Web of Science ®Google Scholar
• Aires CCP, Ijlst L, Stet F, Prip-Buus C, Tavares de Almeida I, Duran M, Inhibition of hepatic palmitoyl-trasnferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol. 2010;79:792–9.
   PubMed Web of Science ®Google Scholar
• Tutor-Crespo MJ, Hermida J, Tutor JC. Assessment of copper status in epileptic patients treated with anticonvulsant drugs by measuring the specific oxidase activity of ceruloplasmin. Epilepsy Res. 2003;56:147–53.
   PubMedGoogle Scholar
• Kuzuya T, Amioka K, Nabeshima T. Valproic acid increases biliary copper excretion in the rat. Epilepsy Res. 2002;51:279–85.
   PubMedGoogle Scholar
• Lampón N, Tutor JC. Effect of valproic acid treatment on copper availability in adult epileptic patients. Clin Biochem. 2010;43:1074–8.
   PubMed Web of Science ®Google Scholar
• Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L, Copper availability contributes to iron perturbations in human non-alcoholic fatty liver disease. Gastroenterol. 2008;135:680–8.
   PubMedGoogle Scholar
• Aigner E, Strasser M, Haufe H, Sonnweber T, Hohla F, Stadlmayr A, A role for low hepatic copper concentrations in non-alcoholic fatty liver disease. Am J Gastroenterol. 2010;105:1978–85.
   PubMed Web of Science ®Google Scholar
• Geubel AP, Gregoire V, Rahier J, Lissens W, Dive C. Hypoceruloplasminemia and ultrastructural changes resembling Wilson's disease in non-alcoholic liver steatosis. A clinical and pathological study of five cases. Liver. 1988;8:299–306.
   PubMedGoogle Scholar
• Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7.
   PubMed Web of Science ®Google Scholar
• Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonografic characteristics. Int J Clin Exp Med. 2010;3:202–10.
   PubMed Web of Science ®Google Scholar
• Koda M, Kawakami M, Murawaki Y, Senda M. The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal Studies. J Gastroenterol. 2007;42:97–103.
   Google Scholar
• de Abreu MRA, Ramos APP, Vendramini RC, Brunetti IL, Pepato MT. Steatosis and hepatic markers before and shortly after bariatric surgery. Ann Clin Biochem. 2007;44:63–9.
   PubMedGoogle Scholar
• Musso G, Gambino R, Durazzo M, Cassader M. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology. 2010;51:715–17.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia, Clinical, laboratory and histological associations in adults with nanalcoholic fatty liver disease. Gastroenterology. 2010;52:913–24.
   Google Scholar
• Nomura F, Ohnishi K, Koen H, Hiyama Y, Nakayama T, Itoh Y, Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol. 1986;8:599–602.
   PubMedGoogle Scholar
• Iwasaki T, Yoneda M, Nakajima A, Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med. 2007;46:1633–9.
   PubMed Web of Science ®Google Scholar
• Louro MO, Tutor JC. Determinación de la actividadoxidásica de la ceruloplasmina en los analizadoresCobas Bio y CobasFara. Acta Bioquim Clin Latinoam. 1991;25:119–25.
   Google Scholar
• Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCVcoinfection. Hepatology. 2006;43:1317–25.
   PubMed Web of Science ®Google Scholar
• Kaito K, Otsubo H, Usui N, Yoshida M, Tanno J, Kurihara E, Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Hematol. 2005;128:698–702.
   PubMed Web of Science ®Google Scholar
• Bowles KM, Cooke LJ, Richards EM, Baglin TP. Platelet size has diagnostic predictive value in patients with thrombocytopenia. Clin Lab Hematol. 2005;27:370–3.
   PubMedGoogle Scholar
• Osselaer JC, Lamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem. 1997;43:1072–6.
   PubMed Web of Science ®Google Scholar
• Milne DB. Copper intake and assessment of copper status. Am J Clin Nutr. 1998;Suppl67:1041S–45S.
   Google Scholar
• Milne DB. Trace elements. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry, Fifth edition. Philadelphia: WB Saunders Company; 2001. p. 568–83.
   Google Scholar
• Chiang CH, Huang CC, Chan WL, Chen JW, Leu HB. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem. 2010;43:1399–404.
   PubMed Web of Science ®Google Scholar
• Turecki L, Kupkova V, Mojto V, Smutny M, Uhlikova E, Vozar I. Serum activity of cholinesterase activity and proteosynthetic function of liver in patients with diabetes mellitus. Bratisl Lek Listy. 2005;106:266–9.
   PubMedGoogle Scholar
• Sridar GR, Rao AA, Srinivas K, Nirmala G, Lakshmi G, Suryanarayna D, Butyrylcholinesterase in metabolic syndrome. Med Hypotheses. 2010;75:648–51.
   PubMedGoogle Scholar
• Kawasaki S, Hasegawa O, Satoh S, Numata K, Terauchi Y. Sonographic assessment of fatty liver using the measurement of para-and perirenal fat thickness. J Clin Ultrasound. 2010;38:470–4.
   PubMedGoogle Scholar
• Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit. 2007;13:RA124–1.
   Google Scholar
• Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes and Alzheimer's disease. Med Hypotheses. 2007;69:1272–6.
   PubMed Web of Science ®Google Scholar
• Puche E, Garcia-Morillas M, Garcia de la Serrana H, Mota C. Probable pseudocholinesterase induction by valproic acid, carbamazepine and phenytoin leading to increasedserum aspirin-esterase activity in epileptics. Int J Clin Pharm Res. 1989;9:309–11.
   PubMedGoogle Scholar
• Tutor-Crespo MJ, Hermida J, Tutor JC. Possible induction of cholinesterase in epileptic patients treated with anticonvulsant drugs: relationship with lipoprotein levels. J Clin Pharmacol. 2004;44:974–80.
   PubMedGoogle Scholar
• Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, Effects of antiepileptic drugs on lipids, homocysteine, and c-reactive protein. Ann Neurol. 2009;65:448–56.
   PubMed Web of Science ®Google Scholar
• Tao TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang WN, Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia. 2009;50:1579–86.
   PubMedGoogle Scholar
• Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47:1136–43.
   PubMedGoogle Scholar
• Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology. 2010;51:603–14.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Muramoto Y, Hori M, Mihara S, Marubayashi T, Nakagawa K. A preliminary investigation of the association between haptoglobin polymorphism, serum ferritin concentration and fatty liver disease. Cin Chim Acta. 2008;398:34–8.
   PubMedGoogle Scholar